Tenecteplase or Alteplase: What Is the Thrombolytic Agent of the Future?

Feigin VL, Stark BA, Johnson CO, Roth GA, Bisignano C, Abady GG, et al. Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet Neurology. 2021;20(10):795–820.

Article  CAS  Google Scholar 

Berge E, Whiteley W, Audebert H, De Marchis GM, Fonseca AC, Padiglioni C, et al. European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke. European stroke journal. 2021;6(1):I-LXII.

NINDS. Tissue plasminogen activator for acute ischemic stroke. New Engl J Med. 1995;333(24):1581–8.

Bivard A, Lin L, Parsons MW. Review of stroke thrombolytics. J Stroke. 2013;15(2):90–8.

Article  Google Scholar 

Brown SG, Macdonald SP, Hankey GJ. Do risks outweigh benefits in thrombolysis for stroke? BMJ. 2013;347: f5215.

Article  Google Scholar 

Smith C, Al-Nuaimi Y, Wainwright J, Sherrington C, Singh A, Kallingal J, et al. The influence of bolus to infusion delays on plasma tissue plasminogen activator levels. Int J Stroke. 2014;9(7):939–42.

Article  Google Scholar 

Acheampong P, May MT, Ford GA, Dixit AK. Bolus-infusion delays of alteplase during thrombolysis in acute ischaemic stroke and functional outcome at 3 months. Stroke research and treatment. 2014;2014:358640-.

Emberson J, Lees KR, Lyden P, Blackwell L, Albers G, Bluhmki E, et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet. 2014;384(9958):1929–35.

Article  CAS  Google Scholar 

Lapchak PA, Araujo DM, Zivin JA. Comparison of tenecteplase with alteplase on clinical rating scores following small clot embolic strokes in rabbits. Exp Neurol. 2004;185(1):154–9.

Article  CAS  Google Scholar 

Van De Werf F, Adgey J, Ardissino D, Armstrong PW, Aylward P, Barbash G, et al. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet. 1999;354(9180):716–22.

Article  Google Scholar 

ASSENT-4. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial. Lancet. 2006;367(9510):569–78.

Armstrong PW, Gershlick AH, Goldstein P, Wilcox R, Danays T, Lambert Y, et al. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med. 2013;368(15):1379–87.

Article  CAS  Google Scholar 

Armstrong PW, Zheng Y, Westerhout CM, Rosell-Ortiz F, Sinnaeve P, Lambert Y, et al. Reduced dose tenecteplase and outcomes in elderly ST-segment elevation myocardial infarction patients: Insights from the strategic reperfusion early after myocardial infarction trial. Am Heart J. 2015;169(6):890-8.e1.

Article  CAS  Google Scholar 

Armstrong PW, Bogaerts K, Welsh R, Sinnaeve PR, Goldstein P, Pages A, et al. The second strategic reperfusion early after myocardial infarction (STREAM-2) study optimizing pharmacoinvasive reperfusion strategy in older ST-elevation myocardial infarction patients. Am Heart J. 2020;226:140–6.

Article  CAS  Google Scholar 

Haley EC Jr, Thompson JL, Grotta JC, Lyden PD, Hemmen TG, Brown DL, et al. Phase IIB/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial. Stroke. 2010;41(4):707–11.

Article  CAS  Google Scholar 

Parsons M, Spratt N, Bivard A, Campbell B, Chung K, Miteff F, et al. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N Engl J Med. 2012;366(12):1099–107.

Article  CAS  Google Scholar 

Huang X, Cheripelli BK, Lloyd SM, Kalladka D, Moreton FC, Siddiqui A, et al. Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study. The Lancet Neurology. 2015;14(4):368–76.

Article  CAS  Google Scholar 

Huang X, MacIsaac R, Thompson JL, Levin B, Buchsbaum R, Haley EC Jr, et al. Tenecteplase versus alteplase in stroke thrombolysis: an individual patient data meta-analysis of randomized controlled trials. Int J Stroke. 2016;11(5):534–43.

Article  Google Scholar 

Bivard A, Huang X, Levi CR, Spratt N, Campbell BCV, Cheripelli BK, et al. Tenecteplase in ischemic stroke offers improved recanalization. Neurology. 2017;89(1):62–7.

Article  Google Scholar 

Bivard A, Huang X, McElduff P, Levi CR, Campbell BCV, Cheripelli BK, et al. Impact of computed tomography perfusion imaging on the response to tenecteplase in ischemic stroke. Circulation. 2017;135(5):440–8.

Article  CAS  Google Scholar 

• Kvistad CE, Næss H, Helleberg BH, Idicula T, Hagberg G, Nordby LM, et al. Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial. The Lancet Neurol. 2022. Recently published trial of higher dose 0.4mg/kg tenecteplase which was stopped early due to safety concerns.

Campbell BCV, Mitchell PJ, Churilov L, Yassi N, Kleinig TJ, Dowling RJ, et al. Tenecteplase versus alteplase before thrombectomy for ischemic stroke. N Engl J Med. 2018;378(17):1573–82.

Article  CAS  Google Scholar 

Campbell BCV, Mitchell PJ, Churilov L, Yassi N, Kleinig TJ, Dowling RJ, et al. Effect of intravenous tenecteplase dose on cerebral reperfusion before thrombectomy in patients with large vessel occlusion ischemic stroke: the EXTEND-IA TNK part 2 randomized clinical trial. JAMA. 2020;323(13):1257–65.

Article  CAS  Google Scholar 

Bivard A, Zhao H, Churilov L, Campbell BCV, Coote S, Yassi N, et al. Comparison of tenecteplase with alteplase for the early treatment of ischaemic stroke in the Melbourne mobile stroke unit (TASTE-A): a phase 2, randomised, open-label trial. The Lancet Neurol. 2022.

• Burgos AM, Saver JL. Evidence that tenecteplase is noninferior to alteplase for acute ischemic stroke. Stroke. 2019;50(8):2156–62. Meta-analysis of previous tenecteplase vs alteplase trials which suggested there was sufficient evidence to establish non-inferiority.

Article  CAS  Google Scholar 

Zhong CS, Beharry J, Salazar D, Smith K, Withington S, Campbell BC, et al. Routine use of tenecteplase for thrombolysis in acute ischemic stroke. Stroke. 2021;52(3):1087–90.

Article  CAS  Google Scholar 

Warach S MJ, Allen L, Ding M-C, Ellington K, Jefferson J, et al. Prospective observational cohort study of tenecteplase as standard of care thrombolysis in a multi-hospital network. Initial safety and feasibility results. Int Stroke Confer; February 19–21, 2020; Los Angeles. 2020.

Gerschenfeld G, Smadja D, Turc G, Olindo S, Laborne FX, Yger M, et al. Functional outcome, recanalization, and hemorrhage rates after large vessel occlusion stroke treated with tenecteplase before thrombectomy. Neurology. 2021;97(22):e2173–84.

Article  CAS  Google Scholar 

Warach SJ, Saver JL. Stroke thrombolysis with tenecteplase to reduce emergency department spread of coronavirus disease 2019 and shortages of alteplase. JAMA Neurol. 2020;77(10):1203–4.

Article  Google Scholar 

Parsons M, Churilov L, Schutte AE, Levi C. Tenecteplase (and common sense) in short supply during the COVID-19 pandemic. Med J Australia. 2020.

• Sajobi T, Singh N, Almekhlafi MA, Buck B, Ademola A, Coutts SB, et al. Alteplase compared to tenecteplase in patients with acute ischemic stroke (AcT) trial: protocol for a pragmatic registry linked randomized clinical trial. Stroke: Vascular and Interventional Neurology. 2021;0(0):e12329. Protocol of a recently completed study with findings presented at ESOC 2022 in May demonstrating non-inferiority of tenecteplase compared with alteplase.Can be replaced with recently published results:Menon BK, Buck BH, Singh N, Deschaintre Y, Almekhlafi MA, Coutts SB et al. Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial Lancet 2022; 400: 161–69.Recently completed comparison of tenecteplase and alteplase in unselected acute stroke <4.5h.

Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2019;50(12):e344–418.

Article  Google Scholar 

Campbell BCV, Ma H, Ringleb PA, Parsons MW, Churilov L, Bendszus M, et al. Extending thrombolysis to 4·5-9 h and wake-up stroke using perfusion imaging: a systematic review and meta-analysis of individual patient data. Lancet. 2019;394(10193):139–47.

Article  Google Scholar 

Ma H, Campbell BCV, Parsons MW, Churilov L, Levi CR, Hsu C, et al. Thrombolysis guided by perfusion imaging up to 9 hours after onset of stroke. N Engl J Med. 2019;380(19):1795–803.

Article  Google Scholar 

Thomalla G, Cheng B, Ebinger M, Hao Q, Tourdias T, Wu O, et al. DWI-FLAIR mismatch for the identification of patients with acute ischaemic stroke within 4·5 h of symptom onset (PRE-FLAIR): a multicentre observational study. The Lancet Neurology. 2011;10(11):978–86.

Article  Google Scholar 

Thomalla G, Simonsen CZ, Boutitie F, Andersen G, Berthezene Y, Cheng B, et al. MRI-guided thrombolysis for stroke with unknown time of onset. N Engl J Med. 2018;379(7):611–22.

Article  Google Scholar 

Roaldsen MB, Lindekleiv H, Eltoft A, Jusufovic M, Søyland MH, Petersson J, et al. Tenecteplase in wake-up ischemic stroke trial: protocol for a randomized-controlled trial. Int J Stroke. 2021;16(8):990–4.

Article  Google Scholar 

Khatri P, Kleindorfer DO, Devlin T, Sawyer RN Jr, Starr M, Mejilla J, et al. Effect of alteplase vs aspirin on functional outcome for patients with acute ischemic stroke and minor nondisabling neurologic deficits: the PRISMS randomized clinical trial. JAMA. 2018;320(2):156–66.

Article  CAS  Google Scholar 

Dawson J, Merwick Á, Webb A, Dennis M, Ferrari J, Fonseca AC. European stroke organisation expedited recommendation for the use of short-term dual antiplatelet therapy early after minor stroke and high-risk TIA. Europ Stroke J. 2021;6(2):CLXXXVII-CXCI.

Kleindorfer DO, Towfighi A, Chaturvedi S, Cockroft KM, Gutierrez J, Lombardi-Hill D, et al. 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association/American Stroke Association. Stroke. 2021;52(7):e364–467.

Article  Google Scholar 

Coutts SB, Dubuc V, Mandzia J, Kenney C, Demchuk AM, Smith EE, et al. Tenecteplase-tissue-type plasminogen activator evaluation for minor ischemic stroke with proven occlusion. Stroke. 2015;46(3):769–74.

Article  CAS  Google Scholar 

Muir KW. Should tenecteplase replace alteplase for acute thrombolysis? Stroke. 2021;52(3):1091–3.

Article  CAS  Google Scholar 

Chester KW, Corrigan M, Schoeffler JM, Shah M, Toy F, Purdon B, et al. Making a case for the right ‘-ase’ in acute ischemic stroke: alteplase, tenecteplase, and reteplase. Expert Opin Drug Saf. 2019;18(2):87–96.

Article  CAS  Google Scholar 

留言 (0)

沒有登入
gif